Introduction

Although bacteria and viruses account for a large number of the infectious diseases that afflict humans, many serious illnesses are caused by eukaryotic organisms. One example is malaria, which is caused by Plasmodium, a eukaryotic organism transmitted through mosquito bites. Malaria is a major cause of morbidity (illness) and mortality (death) that threatens 3.4 billion people worldwide.¹ In severe cases, organ failure and blood or metabolic abnormalities contribute to medical emergencies and sometimes death. Even after initial recovery, relapses may occur years later. In countries where malaria is endemic, the disease represents a major public health challenge that can place a tremendous strain on developing economies.

Worldwide, major efforts are underway to reduce malaria infections. Efforts include the distribution of insecticide-treated bed nets and the spraying of pesticides. Researchers are also making progress in their efforts to develop effective vaccines.² In late 2021, R21/Matrix-M became the first vaccine to be recommended for widespread use by the World Health Organization. At least ten other candidate vaccines are in development. The effort is an multinational one involving governments, universities, nonprofits, philanthropists, and pharmaceutical companies. Much of the recent progress can be credited to organizations within the most affected countries, such as the Malaria Research and Training Center in Mali. Founded by Ogobara Duombo and Yeya Touré in the 1990s, the center has emerged as a primary front-line research driver, including running many of the critical clinical trials that are so important to vaccine development and approval.